Efpeglenatide对2型糖尿病心血管和肾脏结局的影响
这项随机、安慰剂对照试验在28国344中心纳入4076例2型糖尿病合并心血管病史或当前肾病(eGFR 25.0–59.9 ml/min/1.73 m2)加至少一项其他心血管危险因素者,按1:1:1随机接受每周皮下efpeglenatide 4 mg、6 mg或安慰剂。中位随访1.81年,efpeglenatide组MACE发生7.0% vs 安慰剂9.2%(HR 0.73,95%CI 0.58–0.92;优效性P=0.007),肾脏复合结局13.0% vs 18.4%(HR 0.68,95%CI 0.57–0.79;P<0.001)。efpeglenatide组腹泻、便秘、恶心、呕吐或腹胀更常见。
要点
- 适用人群为2型糖尿病合并心血管病史,或当前肾病(eGFR 25.0–59.9 ml/min/1.73 m2)加至少一项其他心血管危险因素者。
- efpeglenatide 4或6 mg每周皮下注射较安慰剂降低MACE:7.0% vs 9.2%,HR 0.73(95%CI 0.58–0.92),优效性P=0.007。
- 肾脏复合结局(肾功能下降或大量白蛋白尿)13.0% vs 18.4%,HR 0.68(95%CI 0.57–0.79),P<0.001。
- 随机化按是否使用SGLT2抑制剂分层,提示该人群中可与SGLT2抑制剂背景治疗并存。
- efpeglenatide组腹泻、便秘、恶心、呕吐或腹胀发生率高于安慰剂,床旁需关注胃肠道耐受性。
适用人群与场景
- 2型糖尿病合并心血管病史,或当前肾病(eGFR 25.0–59.9 ml/min/1.73 m2)加至少一项其他心血管危险因素者。
- 研究在28国344中心开展,随机化按是否使用SGLT2抑制剂分层;原文未提及急诊或ICU场景。
诊断标准与关键阈值
- 肾病定义为eGFR 25.0–59.9 ml/min/1.73 m2(原文未提及其他肾病标准)。
- 主要终点MACE为复合终点:非致死性心肌梗死、非致死性卒中或心血管/未确定原因死亡。
- 肾脏复合结局为肾功能下降或大量白蛋白尿(原文未给出具体阈值)。
处置流程与药物剂量
- efpeglenatide 4 mg或6 mg,每周皮下注射一次;对照为安慰剂。
- 原文未提及急诊/ICU情境下的起始、滴定或停药流程。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 随机、安慰剂对照试验,28国344中心,纳入4076例(efpeglenatide组2717例,安慰剂组1359例),中位随访1.81年。
- MACE:efpeglenatide组7.0%(3.9事件/100人年)vs 安慰剂组9.2%(5.3事件/100人年),HR 0.73(95%CI 0.58–0.92),非劣效性P<0.001,优效性P=0.007。
- 肾脏复合结局:13.0% vs 18.4%,HR 0.68(95%CI 0.57–0.79),P<0.001。
- efpeglenatide组腹泻、便秘、恶心、呕吐或腹胀更常见。
证据类型、等级与局限
- 证据类型:随机、安慰剂对照试验(RCT),由Sanofi资助(AMPLITUDE-O,NCT03496298)。
- 局限:随访中位1.81年;主要终点事件数有限(efpeglenatide组189例,安慰剂组125例);胃肠道不良反应更常见。
对床旁实践的改变
- 对2型糖尿病合并心血管病史或肾病(eGFR 25.0–59.9 ml/min/1.73 m2)加其他心血管危险因素者,可考虑每周皮下efpeglenatide 4或6 mg以降低MACE和肾脏复合结局风险。
- 原文未提供急诊/ICU床旁使用该药的流程或剂量调整方案,床旁决策应依据原文适用人群和剂量。
- 需关注胃肠道不良反应(腹泻、便秘、恶心、呕吐、腹胀)的发生。
指南或共识出处
- AMPLITUDE-O试验(ClinicalTrials.gov NCT03496298),发表于N Engl J Med;原文未提及其他指南或共识。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect of an exendin-based GLP-1 receptor agonist, efpeglenatide, on cardiovascular and renal outcomes in patients with type 2 diabetes who are also at high risk for adverse cardiovascular events is uncertain.
METHODS: In this randomized, placebo-controlled trial conducted at 344 sites across 28 countries, we evaluated efpeglenatide in participants with type 2 diabetes and either a history of cardiovascular disease or current kidney disease (defined as an estimated glomerular filtration rate of 25.0 to 59.9 ml per minute per 1.73 m2 of body-surface area) plus at least one other cardiovascular risk factor. Participants were randomly assigned in a 1:1:1 ratio to receive weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg or placebo. Randomization was stratified according to use of sodium-glucose cotransporter 2 inhibitors. The primary outcome was the first major adverse cardiovascular event (MACE; a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular or undetermined causes).
RESULTS: A total of 4076 participants were enrolled; 2717 were assigned to receive efpeglenatide and 1359 to receive placebo. During a median follow-up of 1.81 years, an incident MACE occurred in 189 participants (7.0%) assigned to receive efpeglenatide (3.9 events per 100 person-years) and 125 participants (9.2%) assigned to receive placebo (5.3 events per 100 person-years) (hazard ratio, 0.73; 95% confidence interval [CI], 0.58 to 0.92; P<0.001 for noninferiority; P = 0.007 for superiority). A composite renal outcome event (a decrease in kidney function or macroalbuminuria) occurred in 353 participants (13.0%) assigned to receive efpeglenatide and in 250 participants (18.4%) assigned to receive placebo (hazard ratio, 0.68; 95% CI, 0.57 to 0.79; P<0.001). Diarrhea, constipation, nausea, vomiting, or bloating occurred more frequently with efpeglenatide than with placebo.
CONCLUSIONS: In this trial involving participants with type 2 diabetes who had either a history of cardiovascular disease or current kidney disease plus at least one other cardiovascular risk factor, the risk of cardiovascular events was lower among those who received weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg than among those who received placebo. (Funded by Sanofi; AMPLITUDE-O ClinicalTrials.gov number, NCT03496298.).
参考来源
- Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021. PMID: 34215025. doi:10.1056/NEJMoa2108269
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。